Renaissance Capital logo

Fulcrum Therapeutics Priced, Nasdaq: FULC

Developing small molecule therapies based on gene regulation for rare diseases.

Industry: Health Care

Latest Trade: $5.84 0.00 (0.0%)

First Day Return: -15.6%

Return from IPO: -63.5%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases. We have developed a proprietary product engine that we employ to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat the known root cause of genetically defined diseases. We are using our product engine to identify targets that can be drugged by small molecules regardless of the particular underlying mechanism of gene mis-expression. We have identified drug targets to treat the root causes of facioscapulohumeral muscular dystrophy, or FSHD, and certain hemoglobinopathies, namely sickle cell disease, or SCD, and b-thalassemia. We expect to initiate a Phase 2b clinical trial of losmapimod, our product candidate for FSHD, in mid-2019. We commenced a Phase 1 clinical trial in February 2019 to obtain safety and tolerability data for losmapimod in patients with FSHD. We plan to submit an investigational new drug application, or IND, for FTX-HbF, our product candidate for certain hemoglobinopathies, in mid-2020.
more less
IPO News for Fulcrum Therapeutics
more
IPO Data
IPO File Date 06/21/2019
Offer Price $16.00
Price Range $16.00 - $18.00
Offer Shares (mm) 4.5
Deal Size ($mm) $72
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 07/17/2019
Offer Price $16.00
Price Range $16.00 - $18.00
Offer Shares (mm) 4.5
Deal Size ($mm) $72
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Cambridge, MA
Founded 2015
Employees 62
Website www.fulcrumtx.com